

**Title: Association Between Lifetime Classic Psychedelic Use and Hypertension in the
Past Year**

Short Title: Classic Psychedelics and Hypertension

Authors: Otto Simonsson, MA (corresponding author)¹, Peter S. Hendricks, PhD², Robin
Carhart-Harris, PhD³, Hannes Kettner, MSc³, Walter Osika, M.D., PhD^{4, 5, 6}

¹Department of Sociology, University of Oxford, UK

²Department of Health Behavior, University of Alabama at Birmingham, US

³Centre for Psychedelic Research, Imperial College London, UK

⁴Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute,
Sweden

⁵Center for Social Sustainability, Department of Neurobiology, Care Sciences and Society,
Karolinska Institute, Sweden

⁶Northern Stockholm Psychiatry, Stockholm Health Care Services, Region Stockholm,
Sweden

Corresponding Author Contact Details

Otto Simonsson, Department of Sociology, University of Oxford

otto.simonsson@trinity.ox.ac.uk, Trinity College, Broad Street, OX1 3BH, Oxford, UK,
+447771067772

ORCID numbers

Otto Simonsson: 0000-0003-4197-7566

Walter Osika: 0000-0002-1583-7319

Total Word Count: 4358

Abstract

Using data from the National Survey on Drug Use and Health (2005-2014), weighted to be representative of the US adult population, the present study investigated the association between lifetime classic psychedelic use and hypertension in the past year among adults in the United States. The results showed that respondents who reported having used a classic psychedelic at least once in their lifetime had significantly lower odds of hypertension in the past year after adjusting for several potential confounders (adjusted odds ratio (aOR) = 0.86 (0.81-0.91), $p < .0001$). Notably, when analyzing the associations between hypertension and use of the main classes of classic psychedelics, namely tryptamines (N,N-dimethyltryptamine, ayahuasca, and psilocybin), LSD (a lysergamide), and phenethylamines (mescaline, peyote, and San Pedro), only the association with lifetime tryptamine use was significant (aOR = 0.80 (0.73-0.89), $p = .0001$). Though these associations are novel, rigorous randomized controlled trials are warranted to investigate potential causal pathways of classic psychedelics on blood pressure.

Keywords: Classic Psychedelics; Psilocybin; LSD; CVD; Hypertension; Population Studies;

NSDUH

Introduction

The prevalence and costs of hypertension are rising worldwide, and the mechanisms underlying its development and progression are complex.¹⁻⁴ For example, several modifiable risk factors contributing to hypertension have been identified, including cigarette smoking, diet and salt intake, lack of physical exercise/sedentary lifestyle, and alcohol consumption.⁵ There are also associations between chronic stress, internalizing disorders such as depression, anxiety, and addiction, and the subsequent diagnosis of hypertension.⁶⁻⁷ Further, recent evidence suggests that low grade inflammation as well as divergent serotonin system activation are important factors in the pathophysiology of hypertension.⁸⁻¹³

While healthy lifestyle choices can prevent or delay the onset of hypertension and can reduce cardiovascular risk,¹⁴ a major drawback of current lifestyle modification intervention is poor adherence to behavior change over time.¹⁵⁻¹⁶ Hence, new preventive interventions (including more profound and persistent lifestyle changes) are warranted.

Research into the therapeutic potential of serotonin 2A receptor agonist classic psychedelics has re-emerged in the past two decades, but it has focused primarily on mental rather than physical health outcomes. The evidence to date suggests that classic psychedelic-mediated experiences can disrupt engrained thinking and behavioral patterns and can be effective in the treatment of internalizing disorders.¹⁷ For example, two oral doses of psilocybin administered together with psychological support significantly decreased depressive symptoms for patients with treatment-resistant depression at 1 week, 3 months, and 6 months post-treatment.¹⁸⁻¹⁹ Participants were interviewed long after the psychedelic-mediated experiences and many of them reported significant changes in behavior associated with favorable effects on

cardiovascular risk factors, including improvements to diet and exercise and reduced alcohol consumption.²⁰

There are three main classes of classic psychedelics (tryptamines, lysergamides, and phenethylamines) that have unique structural features and neurochemical mechanisms.²¹ Most notably, tryptamines include N,N-dimethyltryptamine (DMT), the DMT-containing admixture ayahuasca, and psilocybin; lysergic acid diethylamide (LSD) comprises the lysergamide class; and phenethylamines include mescaline and the mescaline-containing cacti peyote and San Pedro.²² There have been randomized, placebo-controlled clinical trials to evaluate the mental health effects of classic psychedelics such as psilocybin, ayahuasca, and LSD,²³ but findings from a recent population study suggests that the effects might vary across classes, with tryptamine use associated with the greatest therapeutic potential with regard to mental health.²²

There is little evidence of physiological toxicity for classic psychedelics and the risk of harm to oneself and others is considered low.²⁴⁻²⁷ In fact, research suggests that classic psychedelics could have both immunomodulatory and anti-inflammatory properties, which could be contributing factors to both mental and cardiovascular health.^{10, 28} While classic psychedelics can induce transient increases in heart rate and systolic and diastolic blood pressure,²⁹⁻³¹ the long-term effects of classic psychedelic use on hypertension remain unknown.

The present study analyzed pooled data from the National Survey on Drug Use and Health (NSDUH; 2005-2014) to investigate the association between lifetime classic psychedelic use and hypertension in the past year. Based on the evidence to date, we hypothesized that

lifetime classic psychedelic use would be associated with lower odds of hypertension in the past year. Further, in light of recent evidence from a recent population study,²² we also hypothesized that lifetime tryptamine use would have the strongest association with hypertension in the past year among the main classes of classic psychedelics.

Materials and Methods

Data and Population

The NSDUH is a nationally representative survey in the United States, conducted annually in all 50 states and the District of Columbia. The survey is designed to provide up-to-date information on mental health issues and tobacco, alcohol, and drug use in the general population. The present study used pooled data from NSDUH survey years 2005 to 2014, which contained responses from 381,682 (unweighted) adults aged 18 or above. The data were weighted to reflect the civilian noninstitutionalized population. The NSDUH public-use data files are available on their homepage: <https://www.datafiles.samhsa.gov/study-series/national-survey-drug-use-and-health-nsduh-nid13517>

Variables

The dependent variable was hypertension in the past year. This variable was dichotomous (hypertension reported, hypertension not reported) and derived from the following question:

Which, if any, of these conditions did a doctor or other medical professional tell you that you had in the past 12 months?

Consistent with prior research,³² the independent variable was lifetime classic psychedelic use. Respondents reporting that they had ever, even once, used DMT, ayahuasca, LSD, mescaline, peyote or San Pedro, or psilocybin were coded as positive for lifetime classic psychedelic use, whereas those indicating that they had never used any of these substances were coded as negative.

In addition, control variables included age, sex, ethnoracial identity, educational attainment, annual household income, marital status, self-reported engagement in risky behavior, lifetime use of cocaine, other stimulants, sedatives, tranquilizers, heroin, pain relievers, marijuana, phencyclidine (PCP), 3,4-methylenedioxymethamphetamine (MDMA/ecstasy), inhalants, smokeless tobacco, pipe tobacco, cigar, and cigarettes daily, and age of first alcohol use (see Supplementary Materials for more details on variables).

Statistical Analyses

The present study used weighted descriptive statistics to report the baseline characteristics of lifetime classic psychedelic users versus non-lifetime classic psychedelic users (Table 1), as well as the percentage of respondents with hypertension in the past year, divided into lifetime classic psychedelic use and lifetime use of the main classes of classic psychedelics: tryptamines (DMT, ayahuasca, or psilocybin), LSD, and phenethylamines (mescaline, peyote, or San Pedro; Table 2). Logistic regression was used to calculate adjusted odds ratios with 95 percent confidence intervals and examine the association between lifetime classic psychedelic use and hypertension in the past year (Model 1), as well as the association between lifetime use of the main classes of classic psychedelics (tryptamines, LSD, phenethylamines) and hypertension in the past year (Model 2; Table 3).

The analyses used weights provided by the NSDUH and each of the control variables listed above were included as covariates in the regression models to control for potential sources of confounding. There was no control for multiple comparisons in the present study, but exact p-values are reported to the fourth decimal place, which allows for the application of conservative Bonferroni-type corrections of the reader's choosing. The analyses were conducted using Stata version 16.

Results

Descriptive Statistics

Table 1 displays weighted descriptive statistics of lifetime classic psychedelic users versus non-lifetime classic psychedelic users. Consistent with prior research,³²⁻³³ lifetime classic psychedelic use was more common among middle-aged adults, men, non-Hispanic Whites and non-Hispanic Native Americans/Alaska Natives, individuals with greater educational attainment and income, individuals who had never been married and individuals who were divorced/separated, individuals with greater self-reported engagement in risky behavior, and individuals who reported lifetime use of each of the other illicit substances. Furthermore, lifetime classic psychedelic use was more common among individuals who reported lifetime use of each of the tobacco types, individuals who reported first using alcohol before 20 years of age, and individuals with a history of depression or anxiety.

Table 2 displays the percentage of respondents reporting hypertension in the past year. As seen in the table, the prevalence of hypertension in the past year among respondents who had ever used a classic psychedelic was approximately 67% of that among respondents who had never used a classic psychedelic. Notably, the prevalence of hypertension in the past year

among respondents who had ever used a tryptamine (DMT, ayahuasca, or psilocybin) was approximately 56% of that among respondents who had never used a tryptamine.

Regression Models

Table 3 presents results from regression models testing the association between lifetime classic psychedelic use and hypertension in the past year (Model 1), as well as the association between lifetime use of the main classes of classic psychedelics and hypertension in the past year (Model 2). As illustrated in the table, lifetime classic psychedelic use was associated with a 14% lower odds of hypertension in the past year, but among the main classes of classic psychedelics, only lifetime tryptamine use was significantly associated with hypertension in the past year, with a 20% lower odds.

Robustness Checks

To check the robustness of the findings in the present study, we tested whether the association between lifetime classic psychedelic use and hypertension in the past year differed as a function of mental health history, but the association was broadly similar among those with and without a history of depression and those with and without a history of anxiety. We also included mental health history variables as covariates in additional analyses, without observing major differences from the main findings (see Table S1-S5 in the Supplementary Materials for analyses with mental health history variables). In addition, we tested whether the association between lifetime classic psychedelic use and hypertension in the past year differed as a function of recency of classic psychedelic use. Among the variables analyzed in the present study, the NSDUH only assessed recency of use for LSD, but there were no significant associations between recency of LSD use and hypertension in the past year. The main findings remained broadly unchanged when recency of LSD use was included the

regression model (see Table S6 in the Supplementary Materials for analysis with recency of LSD use).

Discussion

The present study investigated the association between lifetime classic psychedelic use and hypertension in the past year. The results showed that respondents who reported having tried a classic psychedelic at least once in their lifetime had significantly lower odds of hypertension. Notably, when analyzing the associations between hypertension and lifetime use of the main classes of classic psychedelics, namely tryptamines (DMT, ayahuasca, psilocybin), LSD (a lysergamide), and phenethylamines (mescaline, peyote, San Pedro), only the association with lifetime tryptamine use was significant.

The novel findings in the current study may be explained by multiple factors, including a) long-term health behavior changes induced by classic psychedelic use;^{20, 34-35} b) improvements in mental health and decreases in chronic stress, which are known risk factors for hypertension;^{6, 36} c) several immunomodulatory and anti-inflammatory effects that are of importance for the development and progression of hypertension;^{8, 10, 21, 37-38} and d) high affinity of some classic psychedelics to serotonin 2A receptors, conferring antihypertensive effects.^{9-10, 12-13} However, caution should be exercised in inferring causality. The present results are primarily conceptualized as a catalyst for further research on the link between classic psychedelic use and long-term trends in blood pressure, with rigorous randomized controlled trials needed to better test cause-and-effect relationships.

The reason that lifetime tryptamine use may be particularly associated with lower risk of hypertension is not easily answerable by the present study. The main classes of classic

psychedelics might typically be taken in unique contexts, with varying frequency and dose, with different intentions, and with varying degrees of psychological support, which could lead to divergent outcomes on health behavior and mental health. It is also possible that the different anti-inflammatory effects, immunomodulatory functions, and pharmacology of each class of classic psychedelics produce unique outcomes on specific measures of physical health. For example, tryptamines have been shown to have affinity for and agonist activity at serotonin 1A receptors. The serotonin 1A receptor has been associated with antidepressant (but possibly also antihypertensive³⁹) effects when activated and could offer a pharmacological explanation for the results in the present study. In addition, previous research suggests that tryptamine use may hold the greatest therapeutic potential with regard to mental health,²² which might also help to explain why lifetime tryptamine use had the strongest association with hypertension in the past year among the three classes of classic psychedelics.

Limitations inherent in the study design warrant consideration. First, causal inference was limited with the cross-sectional design in the current study. While the analysis controlled for multiple plausible confounders, the association between lifetime classic psychedelic use and hypertension in the past year could have been obscured by unmeasured variables that were not included in the NSDUH (e.g. a shared factor that predisposes respondents to healthy lifestyle behaviors associated with hypertension might also predispose them to classic psychedelic use). Second, the NSDUH did not contain information on the set and setting of classic psychedelic use, including context, frequency, dose, intentions, and psychological support. The analysis could therefore not evaluate set and setting-specific associations between classic psychedelic use and hypertension in the past year. Third, the dependent variable was derived from a question based on an indirectly referred opinion from a physician or other medical professional, which could have biased the results. Future research should investigate associations between lifetime classic psychedelic use and clinical measurements of blood

pressure, as well as delineate mechanisms that explain the effect of such use on blood pressure. It would also be important to assess whether potential causal effects vary across different populations.

Conclusion

There has been extensive research on prevention and treatment of hypertension in recent decades, including multiple interventions designed to address modifiable risk factors. Meanwhile, research has also re-emerged on the therapeutic effects of classic psychedelics, but the effects of classic psychedelics on hypertension remain largely unknown. The novel findings in the present study suggest an association between lifetime classic psychedelic use and lower odds of hypertension in the past year, which demonstrates the need for more rigorous research to investigate potential causal pathways of classic psychedelics on blood pressure.

Perspectives

The results showed that lifetime classic psychedelic use was associated with a 14% lower odds of hypertension in the past year and that lifetime tryptamine use was associated with a 20% lower odds of hypertension in the past year. These findings may prove valuable for understanding the physical health outcomes of classic psychedelic use, with rigorous randomized controlled trials warranted to investigate potential causal pathways of classic psychedelics on blood pressure.

Acknowledgments

None.

Sources of Funding

None.

Disclosures

RC-H is a scientific advisor to Enttheon Biomedical, Mydecine, and Synthesis Institute.

Author Contributions

OS conceived of the study and the hypotheses. OS was the primary author who cleaned data, conducted analyses, and drafted the manuscript summarizing the findings. RC-H and HK contributed meaningful expertise on classic psychedelics and commented on draft manuscripts. HK also confirmed the accuracy of the data analyses. PSH contributed meaningful expertise on classic psychedelics and offered important guidance on methodology and statistical analyses. WO contributed meaningful expertise on hypertension. PSH and WO supervised the research project.

References

1. Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard?. *Journal of hypertension*. 2019;37(6):1148-1153. doi: 10.1097/HJH.0000000000002021
2. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nature Reviews Nephrology*. 2020;1-15. doi: 10.1038/s41581-019-0244-2
3. Qamar A, Braunwald, E. Treatment of hypertension: addressing a global health problem. *Jama*. 2018;320(17):1751-1752. doi: 10.1001/jama.2018.16579
4. Fisher ND, Curfman G. Hypertension—a public health challenge of global proportions. *Jama*. 2018;320(17):1757-1759. doi: 10.1001/jama.2018.16760
5. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European heart journal*. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339
6. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nature Reviews Cardiology*. 2018;15(4): 215. doi: 10.1038/nrcardio.2017.189
7. Stein DJ, Aguilar-Gaxiola S, Alonso J, et al. Associations between mental disorders and subsequent onset of hypertension. *General hospital psychiatry*. 2014;36(2):142-149. doi: 10.1016/j.genhosppsych.2013.11.002
8. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. *Nature medicine*. 2019;25(12):1822-1832. doi: 10.1038/s41591-019-0675-0

9. Liolitsa D, Powell JF, Prince M, Lovestone, S. Association study of the 5-HT 2A receptor gene polymorphism, T102C and essential hypertension. *Journal of human hypertension*. 2001;15(5):335-339. doi: 10.1038/sj.jhh.1001177
10. Nichols CD. Serotonin 5-HT_{2A} receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. *Cardiovascular psychiatry and neurology*. 2009. doi: 10.1155/2009/475108
11. Savoia C, Schiffrin EL. Inflammation in hypertension. *Current opinion in nephrology and hypertension*. 2006;15(2):152-158. doi: 10.1097/01.mnh.0000203189.57513.76
12. Villalón CM. The role of serotonin receptors in the control of cardiovascular function. In Tricklebank MD, Daly E, eds. *The Serotonin System*. London, England: Academic Press. 2019; 45-61. doi: 10.1016/C2016-0-04524-2
13. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. *Pharmacological reviews*. 2012;64(2):359-388. doi: 10.1124/pr.111.004697
14. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. *Arterial Hypertension*. 2013;17(2):69-168. doi: 10.3109/08037051.2014.868629
15. Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *European journal of preventive cardiology*. 2019;26(8):824-835. doi: 10.1177/2047487318825350
16. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Annals of internal medicine*. 2001;134(1):1-11. doi: 10.7326/0003-4819-134-1-200101020-00007

17. Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. *JAMA psychiatry*. 2020. doi: 10.1001/jamapsychiatry.2020.2171
18. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology*. 2018;235(2):399-408. doi: 10.1007/s00213-017-4771-x
19. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*. 2016;3(7):619-627. doi: 10.1016/S2215-0366(16)30065-7
20. Watts R, Day C, Krzanowski J, et al. Patients' accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression. *Journal of Humanistic Psychology*. 2017;57(5):520-564. doi: 10.1177/0022167817709585
21. Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. *Frontiers in immunology*. 2015;6:358. doi: 10.3389/fimmu.2015.00358
22. Sexton JD, Nichols CD, Hendricks PS. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. *Frontiers in Psychiatry*. 2019;10:896. doi: 10.3389/fpsy.2019.00896
23. Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A Meta-analysis of Placebo-controlled Trials of Psychedelic-assisted Therapy. *Journal of Psychoactive Drugs*. 2020;1-11. doi: 10.1080/02791072.2020.1769878
24. Nichols DE, Grob CS. Is LSD toxic?. *Forensic science international*. 2018;284:141-145. doi: 10.1016/j.forsciint.2018.01.006
25. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. *The Lancet*. 2010;376(9752):1558-1565. doi: 10.1016/S0140-6736(10)61462-6

26. Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. *Neuropharmacology*. 2018;142:200-218. doi: 10.1016/j.neuropharm.2017.12.040
27. Sessa B. The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. *Psychopharmacology*. 2018;235(2):551-560. doi: 10.1007/s00213-017-4713-7
28. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. *International Review of Psychiatry*. 2018;30(4):363-375. doi: 10.1080/09540261.2018.1481827
29. Dahmane E, Hutson PR, Gobburu JV. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. *Clinical Pharmacology in Drug Development*. 2020. doi: 10.1002/cpdd.796
30. dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JE. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. *Expert review of clinical pharmacology*. 2018;11(9):889-902. doi: 10.1080/17512433.2018.1511424
31. Holze F, Vizeli P, Ley L, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology*. 2020. DOI: 10.1038/s41386-020-00883-6
32. Hendricks PS, Crawford MS, Cropsey KL, et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population. *Journal of psychopharmacology*. 2018;32(1):37-48. doi: 10.1177/0269881117735685
33. Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *Journal of Psychopharmacology*. 2015;29(3):280-288. doi: 10.1177/0269881114565653

34. Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. *Journal of Psychopharmacology*. 2019;33(9):1088-1101. doi: 10.1177/0269881119845793
35. Ona G, Kohek M, Massaguer T, et al. Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. *Journal of psychoactive drugs*. 2019;51(2):135-145. doi: 10.1080/02791072.2019.1567961
36. Chaddha A, Robinson EA, Kline-Rogers E, Alexandris-Souphis T, Rubenfire M. Mental health and cardiovascular disease. *The American journal of medicine*. 2016;129(11):1145-1148. doi: 10.1016/j.amjmed.2016.05.018
37. Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization. *Frontiers in Pharmacology*. 2016;7:35. doi: 10.3389/fphar.2016.00035
38. Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. *Immunology Letters*. 2020. doi: 10.1016/j.imlet.2020.10.001
39. Saxena PR, Villalón CM. Brain 5-HT_{1A} receptor agonism: a novel mechanism for antihypertensive action. *Trends in Pharmacological Sciences*. 1990;11(3):95. doi: 10.1016/0165-6147(90)90187-d

Novelty and Significance

What Is New?

To date, the long-term effects of classic psychedelics on blood pressure remain unknown.

This is the first study to evaluate the association between lifetime classic psychedelic use and hypertension in the past year.

What Is Relevant?

In the present study, lifetime classic psychedelic use was associated with lower odds of hypertension in the past year. Our results serve as a springboard for rigorous randomized controlled trials on the long-term effects of classic psychedelics on blood pressure.

Summary

In conclusion, lifetime classic psychedelic use was associated with lower odds of hypertension in the past year, with several potential confounding variables controlled for in the analyses.

Tables

Table 1. Characteristics of lifetime classic psychedelic users versus non-lifetime classic psychedelic users

Variable	Lifetime classic psychedelic users Weighted %	Non-lifetime classic psychedelic users Weighted %	<i>p</i> value
Age, years			<0.0001
18-25	14.2	14.8	
26-34	21.2	15.0	
35-49	34.1	26.5	
50-64	28.3	24.2	
65 and older	2.3	19.5	
Gender			<0.0001
Male	62.7	45.9	
Female	37.3	54.1	
Race			<0.0001
Non-Hispanic White	83.6	65.3	
Non-Hispanic African American	3.9	12.7	
Non-Hispanic Native American/Alaska Native	1.0	0.4	
Non-Hispanic Native Hawaiian/Pacific Islander	0.2	0.4	
Non-Hispanic Asian	1.3	5.2	
Non-Hispanic more than one race	2.0	1.0	
Hispanic	8.0	15.0	
Education			<0.0001
5 th grade or less	0.3	1.7	
6 th grade	0.2	1.5	
7 th grade	0.2	0.6	
8 th grade	0.9	1.8	
9 th grade	1.8	2.5	
10 th grade	3.1	3.0	
11 th grade	4.7	4.5	
12 th grade	28.2	30.8	
Freshman college year	10.2	8.6	
Sophomore or junior college year	20.3	16.7	
Senior college year or more	30.1	28.4	
Annual household income			<0.0001
Less than \$20,000	17.0	18.7	
\$20,000-\$49,999	30.3	33.3	
\$50,000-\$74,999	17.8	17.3	
\$75,000 or more	34.9	30.7	
Marital status			<0.0001
Married	47.0	54.9	
Widowed	1.7	6.8	
Divorced/separated	18.4	12.9	
Never married	33.0	25.4	
Self-reported engagement in risky behavior			<0.0001
Never	27.3	55.5	

Seldom	44.8	32.4	
Sometimes	25.0	11.1	
Always	2.8	1.1	
Age of first alcohol use			<0.0001
Less than 13 years	19.0	5.2	
13-19 years	76.9	58.6	
More than 20 years	3.4	21.7	
Never used alcohol	0.7	14.4	
Lifetime tobacco use			
Lifetime smokeless tobacco use	41.6	15.6	<0.0001
Lifetime pipe tobacco use	29.7	13.1	<0.0001
Lifetime cigar use	68.8	32.7	<0.0001
Lifetime daily cigarette use	70.2	35.6	<0.0001
Lifetime illicit substance use			
Lifetime cocaine use	71.2	7.3	<0.0001
Lifetime other stimulant use	37.6	3.8	<0.0001
Lifetime sedative use	18.1	1.2	<0.0001
Lifetime tranquilizer use	37.6	5.0	<0.0001
Lifetime heroin use	10.8	0.4	<0.0001
Lifetime pain reliever use	45.9	9.3	<0.0001
Lifetime marijuana use	98.0	36.2	<0.0001
Lifetime MDMA/ecstasy use	32.8	2.0	<0.0001
Lifetime PCP use	17.9	0.4	<0.0001
Lifetime inhalant use	40.0	3.8	<0.0001
Mental health history			
Lifetime depression	21.9	11.3	<0.0001
Lifetime anxiety	15.6	7.4	<0.0001
Total	13.6	86.4	

All percentages were rounded to the nearest 0.1%; cumulative percentages may not add to 100.0. Pearson's chi-squared tests were used to examine the characteristics of lifetime classic psychedelic users versus non-classic psychedelic users. MDMA: 3,4-methylenedioxymethamphetamine; PCP: phencyclidine. Note: lifetime depression and lifetime anxiety were included as covariates in the robustness checks (see Supplementary Materials for robustness checks).

Table 2. Percentage of Respondents with Hypertension in the Past Year

Lifetime Classic Psychedelic Use	Hypertension in the Past Year	
	(%)	(N)
Yes	13.3	4,488
No	19.9	34,454
Lifetime Tryptamine Use	Hypertension in the Past Year	
	(%)	(N)
Yes	11.0	2,686
No	19.8	36,256
Lifetime LSD Use	Hypertension in the Past Year	
	(%)	(N)

Yes	14.1	3,478
No	19.6	35,464
<hr/>		
Lifetime Phenethylamine Use	Hypertension in the Past Year (%)	(N)
Yes	17.9	1,724
No	19.1	37,218

Note: The number of observations was 381,682 (unweighted). Percentage estimates calculated using weights for national representativeness provided by the NSDUH. (N) refers to the unweighted counts of respondents on each row.

Table 3. Lifetime Classic Psychedelic Use Predicting Hypertension in the Past Year

Variable	aOR (95% CI)	p value
<hr/>		
<u>Hypertension in the Past Year</u>		
<u>Model 1</u>		
Lifetime Classic Psychedelic Use	0.86 (0.81-0.91)	<.0001
<hr/>		
<u>Model 2</u>		
Lifetime Tryptamine Use	0.80 (0.73-0.89)	.0001
Lifetime LSD Use	0.96 (0.87-1.05)	.3361
Lifetime Phenethylamine Use	0.97 (0.87-1.08)	.5595

The number of observations was 375,362 (unweighted); aOR: adjusted Odds Ratio; CI: confidence interval. Odds ratios were adjusted for age, sex, ethnoracial identity, educational attainment, annual household income, marital status, self-reported engagement in risky behavior, lifetime use of cocaine, other stimulants, sedatives, tranquilizers, heroin, pain relievers, marijuana, phencyclidine (PCP), 3,4-methylenedioxymethamphetamine (MDMA/ecstasy), inhalants, smokeless tobacco, pipe tobacco, cigar, and cigarettes daily, and age of first alcohol use.